Should I buy or sell MediWound stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares. View MDWD analyst ratings or view top-rated stocks .

What is MediWound's stock price target for 2024?

4 analysts have issued 1 year target prices for MediWound's stock. Their MDWD share price targets range from $25.00 to $36.00. On average, they expect the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 218.7% from the stock's current price. View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts .

How have MDWD shares performed in 2023?

MediWound's stock was trading at $13.49 at the beginning of 2023. Since then, MDWD shares have decreased by 32.5% and is now trading at $9.10. View the best growth stocks for 2023 here .

Are investors shorting MediWound?

MediWound saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 30,200 shares, a decline of 20.9% from the October 31st total of 38,200 shares. Based on an average daily trading volume, of 23,000 shares, the short-interest ratio is presently 1.3 days. Approximately 0.5% of the company's stock are short sold. View MediWound's Short Interest .

When is MediWound's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our MDWD earnings forecast .

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings data on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 44.32% and a negative net margin of 49.79%. During the same quarter last year, the firm earned ($0.91) EPS.

When did MediWound's stock split?

MediWound's stock reverse split on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK) , Sorrento Therapeutics (SRNE) , Blackstone (BX) , Dynavax Technologies (DVAX) , Geron (GERN) , Idera Pharmaceuticals (IDRA) , Mastercard (MA) , SCYNEXIS (SCYX) , Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC) .

Who are MediWound's major shareholders?

MediWound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Yelin Lapidot Holdings Management Ltd. (0.94%), Essex Investment Management Co. LLC (0.57%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of MediWound?

Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

MediWound Stock Price, News & Analysis (NASDAQ:MDWD)

$9.10

+0.25 (+2.82%)

(As of 12/4/2023 ET)

Compare

Today's Range: $8.81
▼
$9.10
50-Day Range: $7.58
▼
$10.87
52-Week Range: $7.10
▼
$14.58

Volume: 11,733 shs
Average Volume: 23,615 shs
Market Capitalization: $83.81 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.00

MediWound MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 218.7% Upside
$29.00 Price Target
Short Interest: Healthy
0.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.98
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.96) to ($1.54) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

516th out of 952 stocks

Medicinals & Botanicals Industry

4th out of 10 stocks

3.5

Analyst's Opinion

Consensus Rating
MediWound has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.00, MediWound has a forecasted upside of 218.7% from its current price of $9.10.
Amount of Analyst Coverage
MediWound has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.46% of the float of MediWound has been sold short.
Short Interest Ratio / Days to Cover
MediWound has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MediWound has recently decreased by 20.94%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MediWound does not currently pay a dividend.
Dividend Growth
MediWound does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MDWD.

3.3

News and Social Media Coverage

News Sentiment
MediWound has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MediWound this week, compared to 1 article on an average week.
Search Interest
1 people have searched for MDWD on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added MediWound to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MediWound insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.20% of the stock of MediWound is held by insiders.
Percentage Held by Institutions
Only 22.32% of the stock of MediWound is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MediWound are expected to decrease in the coming year, from ($0.96) to ($1.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MediWound is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MediWound is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MediWound has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MediWound Stock (NASDAQ:MDWD)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MDWD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MDWD Stock News Headlines

November 27, 2023 | finance.yahoo.com

Does MediWound (MDWD) Have the Potential to Rally 223.05% as Wall Street Analysts Expect?

November 27, 2023 | americanbankingnews.com

Analysts Set Expectations for MediWound Ltd.'s FY2023 Earnings (NASDAQ:MDWD)

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 24, 2023 | markets.businessinsider.com

Mediwound’s Promising Outlook: Buy Rating Justified by Q3 Results and Expanding Market Opportunities

November 22, 2023 | markets.businessinsider.com

Strong Buy Recommendation for Mediwound: Imminent Drivers, Promising Revenue Stream and Solid Financial Footing

November 21, 2023 | benzinga.com

Recap: MediWound Q3 Earnings

November 21, 2023 | finance.yahoo.com

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

November 20, 2023 | msn.com

MediWound Q3 2023 Earnings Preview

December 5, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 14, 2023 | finance.yahoo.com

MediWound to Report Third Quarter 2023 Financial Results

November 13, 2023 | marketwatch.com

MediWound Gets CHMP Positive Opinion for NexoBrid

November 13, 2023 | finanznachrichten.de

MediWound Ltd.: MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid to Treat Pediatric Patients

November 13, 2023 | finance.yahoo.com

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

November 12, 2023 | morningstar.com

MediWound Ltd MDWD

November 8, 2023 | finance.yahoo.com

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

October 19, 2023 | finance.yahoo.com

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

October 12, 2023 | markets.businessinsider.com

Mediwound’s Strategic Collaborations and Supply Continuity Drive Buy Recommendation

October 11, 2023 | markets.businessinsider.com

MediWound Partners 3M For Phase III Study Of EscharEx For Leg Ulcer Treatment

October 9, 2023 | finance.yahoo.com

MediWound Deploys NexoBrid® for Emergency Supply

September 29, 2023 | finance.yahoo.com

MediWound Ltd. (NASDAQ:MDWD) surges 19%; individual investors who own 46% shares profited along with institutions

September 26, 2023 | finance.yahoo.com

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

September 22, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Mediwound (MDWD)

September 21, 2023 | msn.com

MediWound burn therapy NexoBrid launched in US

September 21, 2023 | markets.businessinsider.com

HC Wainwright & Co. Maintains Buy Rating for MediWound: Here's What You Need To Know

September 21, 2023 | markets.businessinsider.com

MediWound Announces Full Commercial Launch Of NexoBrid - Quick Facts

September 21, 2023 | finance.yahoo.com

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

September 11, 2023 | markets.businessinsider.com

MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

See More Headlines

Receive MDWD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediWound and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/21/2023
Today: 12/05/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medicinals & botanicals
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MDWD
CUSIP: N/A
CIK: 1593984
Web: www.mediwound.com
Phone: 972779714100
Fax: 972-77-971-4111
Employees: 83
Year Founded: 2001

Price Target and Rating

Average Stock Price Target: $29.00
High Stock Price Target: $36.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +218.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,600,000.00
Net Margins: -49.79%
Pretax Margin: -49.27%
Return on Equity: -44.32%
Return on Assets: -19.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.31
Quick Ratio: 5.88

Sales & Book Value

Annual Sales: $26.50 million
Price / Sales: 3.16
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.51 per share
Price / Book: 6.03

Miscellaneous

Outstanding Shares: 9,210,000
Free Float: 8,359,000
Market Cap: $83.81 million
Optionable: Not Optionable
Beta: 1.05

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Ofer Gonen B.Sc. (Age 50)
Chief Executive Officer
Comp: $485k
Dr. Lior Rosenberg M.D. (Age 77)
Co-Founder
Comp: $727k
Dr. Ety Klinger MBA (Age 61)
Ph.D., Chief Research & Development Officer
Comp: $393k
Ms. Hani Luxenburg
Chief Financial Officer
Mr. Tzvi Palash B.Sc. (Age 66)
M.Sc., Chief Operating Officer
Mr. Yaron Meyer Adv. (Age 44)
Executive VP, General Counsel & Corporate Secretary
Comp: $240k
Mr. Barry J. Wolfenson (Age 56)
Executive Vice President of Strategy & Corporate Development
Dr. Robert J. Snyder CWS (Age 73)
D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MDWD Stock Analysis - Frequently Asked Questions

Should I buy or sell MediWound stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDWD shares.
View MDWD analyst ratings or view top-rated stocks.
What is MediWound's stock price target for 2024?: 4 analysts have issued 1 year target prices for MediWound's stock. Their MDWD share price targets range from $25.00 to $36.00. On average, they expect the company's stock price to reach $29.00 in the next twelve months. This suggests a possible upside of 218.7% from the stock's current price.
View analysts price targets for MDWD or view top-rated stocks among Wall Street analysts.
How have MDWD shares performed in 2023?: MediWound's stock was trading at $13.49 at the beginning of 2023. Since then, MDWD shares have decreased by 32.5% and is now trading at $9.10.
View the best growth stocks for 2023 here.
Are investors shorting MediWound?: MediWound saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 30,200 shares, a decline of 20.9% from the October 31st total of 38,200 shares. Based on an average daily trading volume, of 23,000 shares, the short-interest ratio is presently 1.3 days. Approximately 0.5% of the company's stock are short sold.
View MediWound's Short Interest.
When is MediWound's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our MDWD earnings forecast.
How were MediWound's earnings last quarter?: MediWound Ltd. (NASDAQ:MDWD) announced its quarterly earnings data on Tuesday, November, 21st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.21. The biopharmaceutical company had revenue of $4.78 million for the quarter, compared to the consensus estimate of $4.73 million. MediWound had a negative trailing twelve-month return on equity of 44.32% and a negative net margin of 49.79%. During the same quarter last year, the firm earned ($0.91) EPS.

When did MediWound's stock split?: MediWound's stock reverse split on Tuesday, December 20th 2022. The 1-7 reverse split was announced on Tuesday, December 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.
What other stocks do shareholders of MediWound own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).
Who are MediWound's major shareholders?: MediWound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Yelin Lapidot Holdings Management Ltd. (0.94%), Essex Investment Management Co. LLC (0.57%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of MediWound?: Shares of MDWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MDWD) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial